DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR RUBRACA
» See Plans and Pricing
All Clinical Trials for rubraca
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02986100 | Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib | Active, not recruiting | Clovis Oncology, Inc. | Phase 1 | 2016-11-01 | The purpose of this study is to characterize the mass balance, absorption, metabolism, and elimination pathways of orally administered [14C] rucaparib followed by cycle by cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation |
| NCT03318445 | Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | Not yet recruiting | Clovis Oncology, Inc. | Phase 1 | 2017-11-01 | This is an open label, non-randomized, dose escalation and expansion Phase Ib trial to evaluate the safety and recommended phase II dose of the combination of irinotecan and rucaparib. |
| NCT03318445 | Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | Not yet recruiting | Pamela Munster | Phase 1 | 2017-11-01 | This is an open label, non-randomized, dose escalation and expansion Phase Ib trial to evaluate the safety and recommended phase II dose of the combination of irinotecan and rucaparib. |
| NCT03442556 | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | Not yet recruiting | National Cancer Institute (NCI) | Phase 2 | 2018-05-15 | This phase II trial studies how well docetaxel, carboplatin, and rucaparib camsylate work in treating patients with castration resistant prostate cancer with homologous recombination deoxyribonucleic acid (DNA) repair deficiency that has spread to other places in the body. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer. |
| NCT03442556 | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | Not yet recruiting | University of Washington | Phase 2 | 2018-05-15 | This phase II trial studies how well docetaxel, carboplatin, and rucaparib camsylate work in treating patients with castration resistant prostate cancer with homologous recombination deoxyribonucleic acid (DNA) repair deficiency that has spread to other places in the body. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for rubraca
Condition Name
Clinical Trial Locations for rubraca
Trials by Country
Clinical Trial Progress for rubraca
Clinical Trial Phase
Clinical Trial Sponsors for rubraca
Sponsor Name
